A PHASE I, MULTIPLE DOSE, OPEN-LABEL PHARMACOKINETIC STUDY OF NIRMATRELVIR/RITONAVIR IN HEALTHY LACTATING WOMEN
Latest Information Update: 07 Apr 2024
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 01 Apr 2024 Status changed from recruiting to completed.
- 27 Nov 2023 Planned End Date changed from 7 Sep 2023 to 15 Dec 2023.
- 27 Nov 2023 Planned primary completion date changed from 7 Sep 2023 to 15 Dec 2023.